Xeris Biopharma Holdings, Inc. (0A8E.L) LSE
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 1.29B |
| Enterprise Value | 1.44B |
| P/E Ratio | -89.6 |
| PEG Ratio | 0.01 |
| Price/Sales Ratio | 4.48 |
| Price/Book Ratio | -154.47 |
| Enterprise/Revenue | 4.98 |
| Enterprise/EBITDA | 101.73 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | June 30, 2026 |
Profitability
| Profit Margin | -0.05 |
| Operating Margin | 0.11 |
AD
Management Effectiveness
| Return On Assets | -0.04 |
| Return On Equity | -4.26 |
Income Statement
| Revenue | 291.85M |
| Revenue/Share | 1.94 |
| Gross Profit | 238.43M |
| EBITDA | 37.05M |
| Net Income | 554,000 |
| Diluted EPS | 0 |
Balance Sheet
| Total Cash | 121.75M |
| Total Cash/Share | 0.7 |
| Total Debt | 289.44M |
| Total Debt/Equity | -29.74 |
| Current Ratio | 1.45 |
| Book Value Per Share | -0.06 |
Price History
| 52-Week Change | 13.39 |
| 52-Week High | 8.73 |
| 52-Week Low | 1.28 |
| Moving Average 50 Days | 2.68 |
| Moving Average 200 Days | 2.36 |
Statistics
| Average Volume | 8,763 |
| Shares Outstanding | 164.93M |
| % Held by Institutions | N/A |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
AD
